Get the Stockscreener App
3.90
17.12%
0.57
Pre-market:
3.94
0.04
+1.03%
Sab Biotherapeutics Inc stock is traded at $3.90, with a volume of 5.96M.
It is up +17.12% in the last 24 hours and up +5.41% over the past month.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
See More
Previous Close:
$3.33
Open:
$3.51
24h Volume:
5.96M
Relative Volume:
7.53
Market Cap:
$298.21M
Revenue:
$114.70K
Net Income/Loss:
$-26.49M
P/E Ratio:
-1.5812
EPS:
-2.4665
Net Cash Flow:
$-53.17M
1W Performance:
+14.71%
1M Performance:
+5.41%
6M Performance:
-2.50%
1Y Performance:
+128.07%
1-Day Range:
$3.44
$4.19
1-Week Range:
$3.30
$4.19
52-Week Range:
$1.65
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Name
Sab Biotherapeutics Inc
Sector
Industry
Phone
305-845-2813
Address
777 W 41ST ST, MIAMI BEACH
Compare SABS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.90 | 298.21M | 114.70K | -26.49M | -53.17M | -2.4665 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-26 | Initiated | Rodman & Renshaw | Buy |
| Dec-19-25 | Initiated | Guggenheim | Buy |
| Sep-17-25 | Initiated | Leerink Partners | Outperform |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Oct-09-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Nov-05-21 | Initiated | Chardan Capital Markets | Buy |
View All
Sab Biotherapeutics Inc Stock (SABS) Latest News
Jefferies raises SAB Biotherapeutics price target on FDA approval By Investing.com - Investing.com Canada
SABS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10.00 - GuruFocus
SABSW Warrants Trade Near Par Value as SAB Biotherapeutics Warrants Hold SteadySell Signal Alerts - newsline.com
SABS Q1 2026 Earnings: EPS Misses Estimates Amid Operational DevelopmentsCFO Commentary Report - newsline.com
SAB Biotherapeutics, Inc. (SABS) Presents at FOCIS 2026 Annual MeetingSlideshow (NASDAQ:SABS) 2026-06-10 - Seeking Alpha
SAB Biotherapeutics (SABS) Edges Lower, Holds Above Key Support Amid Biotechnology Sector CautionSmall Cap Breakouts - newsline.com
Is SAB Biotherapeutics (NASDAQ:SABS) In A Good Position To Deliver On Growth Plans? - Sahm
SABS Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances PipelineLow Estimate Range - newsline.com
SABS Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances Pipeline - newsline.com
SABS - Finviz
SAB Biotherapeutics to Present Data on SAB-142 for Type 1 Diabetes at Upcoming ADA and FOCIS Congresses - Quiver Quantitative
Potential T1D immunotherapy SAB-142 to feature at two June medical meetings - Stock Titan
SABS Technical Analysis & Stock Price Forecast - Intellectia AI
SAB Biotherapeutics (SABS) Slides 3.81% as Biotech Sector Faces Headwinds; Key Support TestedStock Surge Alerts - The Legal Advocate
SABS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Citi Initiates SAB Biotherapeutics(SABS.US) With Buy Rating, Announces Target Price $11 - Moomoo
Citigroup initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation - MSN
SABS Q1 2026 Earnings: Wider-than-Expected Loss as Biotech Continues Development; Shares Edge HigherFinancial Health Score - Newser
Citigroup Initiates SAB Biotherapeutics at Buy With $11 Price Target - marketscreener.com
Jefferies initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation - MSN
SABS Initiated Coverage by Jefferies -- Rating Set to Buy - GuruFocus
Jefferies Initiates SAB Biotherapeutics at Buy With $11 Price Target - Moomoo
Jefferies initiates SAB Biotherapeutics stock with buy on diabetes therapy potential - Investing.com Australia
SAB Biotherapeutics Q1 earnings call highlights - MSN
Why Is SAB Biotherapeutics, Inc. (SABSW) Stock Up Today? - Meyka
SAB Biotherapeutics (SABS) Q1 2026 Miss: What Went WrongCore Business Growth - Newser
Number of shareholders of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView
Certain Restricted Stock Grants of SAB Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-MAY-2026. - marketscreener.com
Certain Warrants of SAB Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-MAY-2026. - marketscreener.com
47,609,899 Common Stock of SAB Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-MAY-2026. - marketscreener.com
Guggenheim Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Perceptive Advisors (SABS) discloses 8.4% ownership — 6.43M shares - Stock Titan
Caligan Partners, David Johnson hold 10.4% of SAB Biotherapeutics (NASDAQ: SABS) - Stock Titan
We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully - Yahoo Finance
Balyasny Asset Mgmt (SABS) discloses ~9.99% ownership, including warrants - Stock Titan
Chardan Capital Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $14 - Moomoo
SAB Biotherapeutics Q1 2026 Earnings Call Transcript - MarketBeat
SAB Biotherapeutics 1Q Research and Development Expenses $13.4M >SABS - Moomoo
SAB Biotherapeutics Q1 Earnings Call Highlights - sharewise.com
H.C. Wainwright raises SAB Biotherapeutics price target on share count By Investing.com - Investing.com Canada
SAB Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
SAB Biotherapeutics (NASDAQ:SABS) Reports Q1 2026 Miss as Clinical Progress and Extended Cash Runway Through 2028 Take Center Stage - ChartMill
Full Transcript: SAB Biotherapeutics Q1 2026 Earnings Call - Benzinga
SAB Biotherapeutics raises $95M, expects trial data in 2H 2027 - Investing.com UK
SAB Biotherapeutics raises $95M, expects trial data in 2H 2027 By Investing.com - Investing.com South Africa
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights - The Manila Times
SAB Biotherapeutics 1Q 2026: Net loss $(18.9M), EPS $(0.35) — 10-Q Summary - TradingView
SAB Biotherapeutics (NASDAQ: SABS) posts larger Q1 2026 loss but boosts cash - Stock Titan
TradingKey - TradingKey
SABS Stock Price, Quote & Chart | SAB BIOTHERAPEUTICS INC (NASDAQ:SABS) - ChartMill
SABS shares surge 7.6% despite SAB Biotherapeutics deeper-than-expected quarterly loss; investors bullish on pipeline prospects.EBITDA Margin - newser.com
Sab Biotherapeutics Inc Stock (SABS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sab Biotherapeutics Inc Stock (SABS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. | Director |
Sep 29 '25 |
Option Exercise |
1.75 |
1,740,000 |
3,045,000 |
2,198,457 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):